Insider Shareholders with Direct Ownership of Kal Vista Pharmaceuticals, Inc. (KALV)
This section provides a comprehensive overview of the insiders with direct ownership of Kal Vista Pharmaceuticals, Inc. (KALV). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
KalVista Pharmaceuticals, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Benjamin L Palleiko
CHIEF EXECUTIVE OFFICER |
397,461 | 181,161 | 250,800 $2.81 Million | 29 |
Sep 09, 2024
Reduced 2.85%
|
| 281,189 | 308,206 | 211,203 $2.37 Million | 35 |
Feb 20, 2024
Reduced 10.54%
|
|
|
Christopher Yea
CHIEF DEVELOPMENT OFFICER |
147,144 | 144,337 | 85,676 $959,571 | 30 |
Aug 23, 2024
Reduced 2.19%
|
|
Paul K. Audhya
CHIEF MEDICAL OFFICER |
139,544 | 61,222 | 83,745 $937,943 | 20 |
Aug 23, 2024
Reduced 2.49%
|
|
Edward P. Feener
CHIEF SCIENTIFIC OFFICER |
208,681 | 226,457 | 72,858 $816,009 | 34 |
May 20, 2024
Reduced 9.99%
|
|
Novo Holdings
> 10% Shareholder |
0 | 2,725,283 | 0 $0 | 3 |
Oct 12, 2017
Reduced 100.0%
|
|
Albert Cha
Director |
18,000 | 18,000 | 0 $0 | 2 |
Sep 11, 2023
Reduced 100.0%
|
|
Michael David Smith
Senior VP, Development |
17,514 | 17,514 | 0 $0 | 4 |
Jun 01, 2021
Reduced 100.0%
|
|
Andreas Maetzel
Senior Vice President, Medical |
88,030 | 88,030 | 0 $0 | 6 |
Apr 29, 2021
Reduced 100.0%
|